Diagnostic Kits/Paper: Difference between revisions
Jump to navigation
Jump to search
AClearwater (talk | contribs) |
No edit summary |
||
| Line 27: | Line 27: | ||
== Our Methodology == | == Our Methodology == | ||
== Forces affecting the GDx Industry == | == Forces affecting the GDx Industry == | ||
* | * Revolutionary technical advances | ||
* Regulatory process | |||
* payer system (public & private insurance) | |||
== Existing and Evolving GDx Models == | == Existing and Evolving GDx Models == | ||
=== Commercialization of Basic Research === | |||
* Licensing of research to existing GDx company | |||
* Licensing of research to new GDx start-up | |||
* Usage of research in public domain by existing GDx company? (multiplex kits?) | |||
=== Paths to Market === | |||
* ASRs | |||
* Kits | |||
* DTC | |||
== Discussion == | == Discussion == | ||
Revision as of 12:42, 3 December 2009
Are patents clogging the pipeline: The effects of intellectual property on commercialization and access to genetic diagnostics
(A Summary Paper of our Research to date)
By Carolina Rossini, Andrew Clearwater, and Mackenzie Cowell
Last Draft: December 3, 2009
Introduction
Description of the GDx Market
Defining Genetic Diagnostics
Brief History of GDx and Related Technology
- chemical patents at turn of century (see Palombi's work)
Overview of IP Landscape
Patent Protection
Bayh-Dole
Licensing
When IP Does and Does Not Work Effectively
Our Research Questions
Our Methodology
Forces affecting the GDx Industry
- Revolutionary technical advances
- Regulatory process
- payer system (public & private insurance)
Existing and Evolving GDx Models
Commercialization of Basic Research
- Licensing of research to existing GDx company
- Licensing of research to new GDx start-up
- Usage of research in public domain by existing GDx company? (multiplex kits?)
Paths to Market
- ASRs
- Kits
- DTC